{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:07:15Z","timestamp":1792145235236,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12094-020-02456-x","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:05:37Z","timestamp":1595631937000},"page":"612-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["MGMT-inhibitor in combination with TGF-\u03b2RI inhibitor or CDK 4\/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-4760","authenticated-orcid":false,"given":"A.","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"F. C.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. B. F.","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kanginakudru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"Infinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"W. A.","family":"Vandergrift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Lindhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cachia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"issue":"2","key":"2456_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000306139","volume":"78","author":"J Zhang","year":"2010","unstructured":"Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD. Acquire resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology. 2010;78(2):103\u201314.","journal-title":"Oncology"},{"issue":"1","key":"2456_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"J Zhang","year":"2012","unstructured":"Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5(1):102\u201314.","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"2456_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1471-4159.2012.07781.x","volume":"122","author":"C Happold","year":"2012","unstructured":"Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem. 2012;122(2):444\u201355.","journal-title":"J Neurochem"},{"issue":"10","key":"2456_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"9","key":"2456_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fonc.2019.01547","volume":"17","author":"W Yu","year":"2020","unstructured":"Yu W, Zhang L, Wei Q, Shao A. O(6)-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol. 2020;17(9):1547.","journal-title":"Front Oncol"},{"issue":"3","key":"2456_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11060-011-0709-z","volume":"106","author":"KE Warren","year":"2012","unstructured":"Warren KE, Gururangan S, Geyer JR, et al. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol. 2012;106(3):643\u20139. https:\/\/doi.org\/10.1007\/s11060-011-0709-z.","journal-title":"J Neurooncol"},{"issue":"13","key":"2456_CR7","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1002\/cncr.24336","volume":"115","author":"JA Quinn","year":"2009","unstructured":"Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 2009;115(13):2964\u201370.","journal-title":"Cancer"},{"issue":"8","key":"2456_CR8","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","volume":"27","author":"JA Quinn","year":"2009","unstructured":"Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27(8):1262\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2456_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40268-017-0180-1","volume":"17","author":"D Lubanska","year":"2017","unstructured":"Lubanska D, Porter L. Revisiting CDK inhibitors for treatment of glioblastoma multiforme. Drugs R D. 2017;17(2):255\u201363.","journal-title":"Drugs R D"},{"issue":"3","key":"2456_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11060-019-03258-0","volume":"144","author":"TW Miller","year":"2019","unstructured":"Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE. Tumor pharmacokinetics and pharmacodynamics of the CDK4\/6 inhibitor ribociclib in patients with recurrent glioblastoma. J Neurooncol. 2019;144(3):563\u201372.","journal-title":"J Neurooncol"},{"issue":"8","key":"2456_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fonc.2018.00608","volume":"12","author":"F Schettini","year":"2018","unstructured":"Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, Arpino G, De Laurentiis M, Puglisi F, De Placido S, Del Mastro L. CDK 4\/6 inhibitors as single agent in advanced solid tumors. Front Oncol. 2018;12(8):608.","journal-title":"Front Oncol"},{"issue":"1","key":"2456_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ijc.32069","volume":"145","author":"E Le Rhun","year":"2019","unstructured":"Le Rhun E, von Achenbach C, Lohmann B, Silginer M, Schneider H, Meetze K, Szabo E, Weller M. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. Int J Cancer. 2019;145(1):242\u201353.","journal-title":"Int J Cancer"},{"key":"2456_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-3-030-30651-9_9","volume":"1202","author":"B Kaminska","year":"2020","unstructured":"Kaminska B, Cyranowski S. Recent advances in understanding mechanisms of TGF beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol. 2020;1202:179\u2013201.","journal-title":"Adv Exp Med Biol"},{"issue":"54","key":"2456_CR14","doi-asserted-by":"publisher","first-page":"6834","DOI":"10.1038\/onc.2008.287","volume":"27","author":"A Pen","year":"2008","unstructured":"Pen A, Moreno MJ, Durocher Y, Deb-Rinker P, Stanimirovic DB. Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene. 2008;27(54):6834\u201344.","journal-title":"Oncogene"},{"issue":"5","key":"2456_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825\u201337.","journal-title":"Invest New Drugs"},{"issue":"12","key":"2456_CR16","doi-asserted-by":"publisher","first-page":"14803","DOI":"10.18632\/oncotarget.7543","volume":"7","author":"BM Ku","year":"2016","unstructured":"Ku BM, Yi SY, Koh J, Bae YH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. The CDK4\/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016;7(12):14803\u201313.","journal-title":"Oncotarget"},{"issue":"10","key":"2456_CR17","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1158\/1535-7163.MCT-14-0257","volume":"13","author":"V Yadav","year":"2014","unstructured":"Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB. The CDK4\/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014;13(10):2253\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"25","key":"2456_CR18","doi-asserted-by":"publisher","first-page":"21614","DOI":"10.18632\/oncotarget.4308","volume":"6","author":"M Serova","year":"2015","unstructured":"Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015;6(25):21614\u2013277.","journal-title":"Oncotarget"},{"issue":"1","key":"2456_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2007.10.008","volume":"44","author":"L Bueno","year":"2008","unstructured":"Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Troc\u00f3niz IF. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008;44(1):142\u201350.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2456_CR20","first-page":"4479","volume":"10","author":"S Herbertz","year":"2015","unstructured":"Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;10(9):4479\u201399.","journal-title":"Drug Des Devel Ther"},{"issue":"14","key":"2456_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471141755.ph1416s52","volume":"14","author":"BL Carlson","year":"2011","unstructured":"Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol. 2011;14(14):1\u201314.16. https:\/\/doi.org\/10.1002\/0471141755.ph1416s52.","journal-title":"Curr Protoc Pharmacol"},{"issue":"6","key":"2456_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00280-018-3684-7","volume":"82","author":"A Das","year":"2018","unstructured":"Das A, Henderson F Jr, Lowe S, Wallace GC 4th, Vandergrift WA 3rd, Lindhorst SM, Varma AK, Infinger LK, Giglio P, Banik NL, Patel SJ, Cachia D. Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018;82(6):945\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2456_CR23","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.1007\/s13277-015-4621-6","volume":"37","author":"A Das","year":"2016","unstructured":"Das A, McDonald DG, Dixon-Mah YN, Jacqmin DJ, Samant VN, Vandergrift WA 3rd, Lindhorst SM, Cachia D, Varma AK, Vanek KN, Banik NL, Jenrette JM 3rd, Raizer JJ, Giglio P, Patel SJ. RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol. 2016;37(6):7525\u201334.","journal-title":"Tumour Biol"},{"key":"2456_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2020.1773844","author":"A Das","year":"2020","unstructured":"Das A, Martinez Santos JL, Alshareef M, et al. In vitro effect of dovitinib (TKI258), a multi-target angiokinase inhibitor on aggressive meningioma cells. Cancer Invest. 2020. https:\/\/doi.org\/10.1080\/07357907.2020.1773844.","journal-title":"Cancer Invest"},{"issue":"4","key":"2456_CR25","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1002\/jcb.27913","volume":"120","author":"BM Johnson","year":"2019","unstructured":"Johnson BM, Radwan FFY, Hossain A, Doonan BP, Hathaway-Schrader JD, God JM, Voelkel-Johnson CV, Banik NL, Reddy SV, Haque A. Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells. J Cell Biochem. 2019;120(4):6264\u201376.","journal-title":"J Cell Biochem"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02456-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T00:24:15Z","timestamp":1627172655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02456-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["2456"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02456-x","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"21 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All used human cell cultures have been preserved because they have characteristics that are vital to the advancement of scientific research and development. These are freely available as public resources by Mayo Clinic and ScienCell Research Laboratories. Therefore, local ethics approval was not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}